Turk Ilac ve Serum Sanayi AS (TRILC) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Turk Ilac ve Serum Sanayi AS (TRILC) has a cash flow conversion efficiency ratio of 0.023x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (TL44.50 Million ≈ $996.76K USD) by net assets (TL1.91 Billion ≈ $42.80 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See Turk Ilac ve Serum Sanayi AS defensive liquidity buffer to measure how many days the company can operate on defensive assets alone.
Turk Ilac ve Serum Sanayi AS - Cash Flow Conversion Efficiency Trend (2018–2024)
This chart illustrates how Turk Ilac ve Serum Sanayi AS's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Turk Ilac ve Serum Sanayi AS Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Turk Ilac ve Serum Sanayi AS ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Plus Therapeutics Inc
NASDAQ:PSTV
|
-1.566x |
|
LMS Co. Ltd
KQ:073110
|
-0.044x |
|
BPL Limited
NSE:BPL
|
0.003x |
|
Is Yatirim Ortakligi AS
IS:ISYAT
|
0.069x |
|
Aveng Ltd
JSE:AEG
|
0.471x |
|
Sow Good Inc. Common Stock
NASDAQ:SOWG
|
1.165x |
|
AJ Bell plc
LSE:AJB
|
0.252x |
|
AGES Industri AB (publ)
ST:AGES-B
|
-0.010x |
Annual Cash Flow Conversion Efficiency for Turk Ilac ve Serum Sanayi AS (2018–2024)
The table below shows the annual cash flow conversion efficiency of Turk Ilac ve Serum Sanayi AS from 2018 to 2024. For the full company profile with market capitalisation and key ratios, see Turk Ilac ve Serum Sanayi AS stock valuation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | TL1.92 Billion ≈ $43.09 Million |
TL-378.48 Million ≈ $-8.48 Million |
-0.197x | -185.55% |
| 2023-12-31 | TL1.78 Billion ≈ $39.76 Million |
TL408.19 Million ≈ $9.14 Million |
0.230x | +1193.03% |
| 2022-12-31 | TL564.69 Million ≈ $12.65 Million |
TL-11.88 Million ≈ $-266.08K |
-0.021x | +90.49% |
| 2021-12-31 | TL324.08 Million ≈ $7.26 Million |
TL-71.67 Million ≈ $-1.61 Million |
-0.221x | -198.67% |
| 2020-12-31 | TL148.13 Million ≈ $3.32 Million |
TL33.20 Million ≈ $743.59K |
0.224x | +9.86% |
| 2019-12-31 | TL65.28 Million ≈ $1.46 Million |
TL13.32 Million ≈ $298.28K |
0.204x | -66.57% |
| 2018-12-31 | TL62.47 Million ≈ $1.40 Million |
TL38.13 Million ≈ $853.93K |
0.610x | -- |
About Turk Ilac ve Serum Sanayi AS
Turk Ilac Ve Serum Sanayi Anonim Sirketi produces and sells human tablets, capsules, ampoules, vials, ointments-creams, intravenous serums, parenteral solutions, nutritional solutions, amino acids, and other chemicals in Turkey. It also offers bulb, biological, and serum products, as well as medical devices. Turk Ilac Ve Serum Sanayi Anonim Sirketi was founded in 2010 and is headquartered in Anka… Read more